In:
British Journal of Haematology, Wiley, Vol. 176, No. 5 ( 2017-03), p. 770-782
Abstract:
The combination of lenalidomide (Revlimid ® , R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rr MM ). With this regimen, only a small fraction of patients will achieve high quality responses [≥ very good partial response ( VGPR )]. The combination of bendamustine (B), lenalidomide and dexamethasone ( BR d) has shown high efficacy in patients with advanced rr MM . However, dose‐limiting haematotoxicity restricted its use in extensively pre‐treated patient populations. This prospective, multicentre Phase II study evaluated the efficacy and safety of BR d in rr MM patients with one prior line of therapy. Fifty patients were enrolled (median age 68·5 years [range 46–83]) and were treated with B 75 mg/m 2 days 1, 2; R 25 mg days 1–21 and d (40/20 mg) days 1, 8, 15 and 22, for 6 28‐day induction cycles, followed by 12 cycles with Rd alone. Pegfilgrastim was administered according to protocol‐defined criteria. The study aimed to demonstrate a complete response ( CR )/ VGPR rate of 〉 40% after induction therapy. Of 45 evaluable patients, 23 (51%) achieved a CR / VGPR . Grade 4 neutropenia or thrombocytopenia occurred in 17 (34%) and 8 (16%) of patients, respectively. BR d is a safe and efficacious regimen as a second line treatment for rr MM , leading to high quality responses in a considerable proportion of patients.
Type of Medium:
Online Resource
ISSN:
0007-1048
,
1365-2141
DOI:
10.1111/bjh.2017.176.issue-5
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
1475751-5
Bookmarklink